← board
ANIX
distress 1/10 · well-funded / low risk$3.48-1%today-33% from 52w high
Lead: triple negative breast cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$14M
Runway
1.9 yrs
Shares 1y
+3%
Price & events
+5.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
+4.8%
1W
+26.1%
1M
+14.5%
3M
+6.7%
6M
+3.0%
1Y
+20.4%
2Y
-18.1%
5Y
+6.4%
All
Overview
- Market Cap
- $118.40M
- Volume
- 37.35K
- 52 Week Range
- $2.35 – $5.22
- Total Shares
- 34.02M
- Float Shares
- 32.17M
- Short %
- 2.75%
- % Held by Insiders
- 5.39%
- % Held by Institutions
- 15.11%
- RVOL
- 0.13x
- Beta
- 0.60
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 6
- 2026-09-10Estimated 45%earningsEarningsEarnings releaseyahoo
- February 10, 2026conferencedata presentationsecondaryPhase 1Lira-cel · Water Tower Research fireside chat to discuss trial observations.SEC 8-K
- 2026-02-09fda agreementLira-cel · Regulatory approval granted for protocol amendment enabling substantial dose escalation.SEC 8-K
- 2025trial initiationsecondaryPhase 2breast cancer vaccine · Planned commencement of Phase 2 neoadjuvant study.SEC 8-K
- December 11, 2025readoutPhase 1investigational breast cancer vaccine (α-lactalbumin) · Final Phase 1 data presented at SABCS 2025.SEC 8-K
- 2024-11-08conferencedata presentationsecondaryPhase 1breast cancer vaccine · Presentation of updated positive Phase 1 data at SITC 39th Annual Meeting.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $10 (+187% upside) · 4 analysts
- 2026-04-08D. Boral CapitalBuy
- 2026-03-31D. Boral CapitalBuy
- 2026-02-04D. Boral CapitalBuy
- 2025-12-12D. Boral CapitalBuy
- 2025-10-07D. Boral CapitalBuy
- 2025-09-22D. Boral CapitalBuy
Competitors — triple negative breast cancer
- LLYELI LILLY & Co$1094.4B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- GILDGILEAD SCIENCES, INC.$159.5B · D2
- BNTXBioNTech SE$23.1B · D1
- EXELEXELIXIS, INC.$13.8B · D0
- NRIXNurix Therapeutics, Inc.$2.4B · D6
- RDPTFRadiopharm Theranostics Ltd$24M · D3
- MDNAFMedicenna Therapeutics Corp.$17M · D6
- BOLTBolt Biotherapeutics, Inc.$8M · D5
- AKTSAktis Oncology, Inc.— · D1
Recent news
- 2026-07-22Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance Singapore
- 2026-07-22CEO Amit Kumar Increases Stake in Anixa Biosciences Inc - GuruFocus
- 2026-07-21Anixa Biosciences (ANIX) CEO buys 5,000 common shares - Stock Titan
- 2026-07-21Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus
- 2026-07-21ANIX – Will be mine - Six9ja
- 2026-07-20Insider Purchase: Director at $ANIX Buys 12,000 Shares - Quiver Quantitative
- 2026-07-20Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock - Stock Titan
- 2026-07-20ANIX – Heart of mine - Six9ja
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.